John Hayslip

Chief Tech/Sci/R&D Officer at VERASTEM, INC.

Health Technology

Consumer Services

Profile

John Hayslip currently works at Verastem, Inc., as Chief Medical Officer from 2024.
Dr. Hayslip also formerly worked at The Markey Cancer Center Foundation, as Director-Clinical Research & Data Management, Nektar Therapeutics, as Vice President-Clinical Development, and I-Mab, as Chief Medical Officer from 2022 to 2024.
Dr. Hayslip received his graduate degree from The Medical University of South Carolina and doctorate degree from Northeast Ohio Medical University.

John Hayslip active positions

Companies	Position	Start
VERASTEM, INC.	Chief Tech/Sci/R&D Officer	18/04/2024

All active positions of John Hayslip

Former positions of John Hayslip

Companies	Position	End
NOVABRIDGE BIOSCIENCES	Chief Tech/Sci/R&D Officer	15/04/2024
The Markey Cancer Center Foundation	Corporate Officer/Principal	-
NEKTAR THERAPEUTICS	Chief Tech/Sci/R&D Officer	-

See the detail of John Hayslip's experience

Training of John Hayslip

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of John Hayslip's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	6
Nektar Therapeutics Nektar Therapeutics Pharmaceuticals: MajorHealth Technology Discovers and develops medicines in areas of high unmet medical need	Health Technology
Medical University of South Carolina Medical University of South Carolina Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
The Markey Cancer Center Foundation
Verastem, Inc. Verastem, Inc. BiotechnologyHealth Technology Discovers and develops drugs	Health Technology
Northeast Ohio Medical University Northeast Ohio Medical University Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
I-Mab I-Mab Pharmaceuticals: MajorHealth Technology Develops and manufactures medicines for cancer and autoimmune diseases	Health Technology